Analysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden

Press/Media: Press / Media

PeriodDec 5 2015

Media coverage

40

Media coverage

  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletBloomberg
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletReuters
    CountryUnited Kingdom
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletPR Newswire
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletPR Newswire
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletPR Newswire
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletIndividual.com
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletSys-Con India
    CountryIndia
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletBioSpace
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletMoneyShow.com
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletTamar Securities
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletFinancial Content
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletReliance Trust
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletWorldNetDaily
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletTown Hall
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletWall Street Business Network
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletMarketplace
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletFat Pitch Financials
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletCEOWorld Magazine
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletRCL Advisors
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletFranklin Credit Management Corporation
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletMarket Pulse Navigator
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletSearchBug
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletIndustrial Info Financials
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletCrawford Financial Planning
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletFreshnews.com
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletUlitzer
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletVirtualization Conference & Expo
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletSys-Con Belgium
    CountryBelgium
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletSys-Con Australia
    CountryAustralia
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletTickerTech.com
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletSys-Con Canada
    CountryCanada
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletTutorial Finder
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletReview Seeker
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletBarchart
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletPharmacy Choice
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletGood Day Sacramento
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletU-T San Diego
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletIndianapolis Business Journal
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletAsk.com
    CountryUnited States
    Date12/5/15
    PersonsRuben Mesa
  • TitleAnalysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date12/5/15
    PersonsRuben Mesa